News | June 07, 2007

Haemoscope Announces Availability of PlateletMapping Assays for Optimal Antiplatelet Therapy

June 8, 2007 — Haemoscope Corporation has developed PlateletMapping assays, combining automated platelet aggregation with the company’s proprietary TEG 5000 (Thrombelastograph) Hemostasis System.

The assays measure inhibited platelet function against maximum platelet function for optimal antiplatelet therapy and demonstrate the degree of inhibition by different platelet inhibitors as well as providing maximum platelet function, which can be used as a reference point for determining an anti-platelet regimen.

The combination of total platelet function and ADP or AA activated platelet function allows detection of drug resistance as well as the therapeutic efficacy of Plavix, aspirin, and GPIIb/IIIa inhibiting drugs. As a result, the PlateletMapping assays provide clinicians with the information needed to personalize a patient’s anti-platelet therapy, based on actual hemostatic state, rather than on body weight or the concept that “one dose fits all.”

As a result, the assays help determine who can go to surgery immediately and who should wait for platelet recovery without the potential risk of an ischemic event. The PlateletMapping assays have received FDA clearance and can be used as a more powerful alternative to current tests for measuring platelet function in hemostasis.

For more information visit: www.haemoscope.com

Related Content

clinical trial study antiplatelet thomas jefferson cath function monitors
News | December 12, 2013
Thomas Jefferson University researchers discovered that the formation of blood clots follows a different molecular...
antiplatelet therapy clinical trial blood test platelet function corgenix
News | November 15, 2013
study conducted in Ireland found that...
Feature | November 14, 2013
Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (...
News | September 23, 2013
Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the...
News | September 05, 2013
September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing,...
News | July 22, 2013
T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical...
Clinical Study Aspirin Duke Medicine Blood Test Platelet Functioning Testing
News | July 12, 2013
Aspirin has been widely used for more than 50 years as a common, inexpensive blood thinner for patients with heart...
cath lab, SYNTAX, SCAI
Feature | July 03, 2013 | Dmitriy N. Feldman, M.D., FACC, FSCAI
The year 2013 has brought us several important clinical trials that have changed the way interventional cardiologists...
UK Blood Clots Teststing Wafarin Self Monitoring
News | April 29, 2013
A simple self-monitoring test could reduce the risk of stroke by half in thousands of people in the United Kingdom who...
Overlay Init